| 40.05 -0.85 (-2.08%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.79 | 1-year : | 52.43 |
| Resists | First : | 42.62 | Second : | 44.88 |
| Pivot price | 41.46  |
|||
| Supports | First : | 38.97 | Second : | 32.42 |
| MAs | MA(5) : | 40.29 | MA(20) : | 42.05 |
| MA(100) : | 52.08 |
MA(250) : | 50.77 |
|
| MACD | MACD : | -1.8  |
Signal : | -2 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 23.2 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 67.66 | Low : | 35.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMPH ] has closed above bottom band by 23.0%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.69 - 41.91 | 41.91 - 42.1 |
| Low: | 39.31 - 39.55 | 39.55 - 39.76 |
| Close: | 39.65 - 40.06 | 40.06 - 40.41 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Thu, 18 Apr 2024
Equities Analysts Offer Predictions for Amphastar Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:AMPH) - MarketBeat
Wed, 17 Apr 2024
Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) CEO Pay Justified? - Yahoo Movies UK
Wed, 17 Apr 2024
3 Reasons Growth Investors Will Love Amphastar (AMPH) - Yahoo Movies UK
Mon, 15 Apr 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading 3% Higher - MarketBeat
Fri, 12 Apr 2024
Shaker Investments LLC OH Increases Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Fri, 12 Apr 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 48 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 22 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 3,670 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | 2.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.3 |
| Profit Margin | 21.3 % |
| Operating Margin | 30.3 % |
| Return on Assets (ttm) | 11 % |
| Return on Equity (ttm) | 23.5 % |
| Qtrly Rev. Growth | 31.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 13.39 |
| EBITDA (p.s.) | 4.94 |
| Qtrly Earnings Growth | 5.5 % |
| Operating Cash Flow | 184 (M) |
| Levered Free Cash Flow | 245 (M) |
| PE Ratio | 15.4 |
| PEG Ratio | 0.4 |
| Price to Book value | 3.01 |
| Price to Sales | 2.98 |
| Price to Cash Flow | 10.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|